FUNDED PROJECTS KWF PROGRAMME RESEARCH & IMPLEMENTATION CALL 2017-I
RESEARCH PROJECTS
Project Project Title Project Leader Institute Department Research Phase Tumor type Modality Assigned Funder Approved budget Number
Clinical evaluation of the benefit of planning based steering to Radiation Oncology 10873 Dr. Petra Kok Academic Medical Center Clinical Cervical Cancer Interventive devices € 326.486,80 improve effectiveness of hyperthermia in cervical cancer patients (Radiotherapy)
Individualized image-guided adaptive radiotherapy for resectable Radiation Oncology 10882 Dr. Astrid van der Horst Academic Medical Center Clinical Stomach Cancer Interventive devices € 611.236,60 gastric cancer: now and in the future (Radiotherapy) Adjuvant hyperthermic intraperitoneal chemotherapy in patients 10961 with colon cancer at high risk of peritoneal carcinomatosis; the Dr. Pieter Tanis Academic Medical Center Surgery Clinical Colon and Rectal Cancer Interventive devices € 41.528,00 COLOPEC randomized multicentre trial. COMBATING THERAPY-INDUCED EPITHELIAL TO MESENCHYMAL Center of Experimental and Creation of 10992 Dr. Maarten Bijlsma Academic Medical Center Oesophageal Cancer Biomarkers € 583.890,26 TRANSITION IN ESOPHAGEAL CANCER Molecular Medicine modality Toxicity prediction in radiotherapy for pelvic cancers, assessing Radiation Oncology 11000 the added value of biological parameters to RT treatment Prof. Coen Rasch Academic Medical Center Clinical Bladder Cancer Biomarkers € 680.516,00 (Radiotherapy) planning variables Long-term outcomes of acute left-sided malignant colonic 11109 obstruction in the Netherlands; value of ‘bridge-to-surgery’ Dr. Pieter Tanis Academic Medical Center Surgery Clinical Gastrointestinal Tract Quality of life / care € 135.099,80 strategy. Targeting miR-139, a novel tumor suppressor in acute myeloid Erasmus University Medical 10948 Dr. Stefan Erkeland Immunology Basic research Leukemia Basic research € 598.347,00 leukemia Center Rotterdam The (cost)effectiveness of neoadjuvant FOLFIRINOX versus Erasmus University Medical 10955 upfront surgery for (borderline) resectable pancreatic cancer. The Dr. Bas Groot Koerkamp Surgery Clinical Pancreatic Cancer Agents Alpe d'HuZes € 523.338,71 Center Rotterdam PREOPANC-2 study.
Dissecting the structural and molecular determinants of DNA Erasmus University Medical Breast Cancer; Not Site-Specific 11008 Dr. Arnab Ray Chaudhuri Molecular Genetics Basic research Basic research € 697.449,00 replication stress in genome instability and tumorigenesis. Center Rotterdam Cancer
Realizing better doctor-patient dialogue about choices in Erasmus University Medical 11086 palliative care and early-phase clinical trial participation: Towards Prof. Carin Van der Rijt Medical Oncology Clinical Not Site-Specific Cancer Quality of life / care € 586.466,50 Center Rotterdam an online value clarification tool. Development of a radiolabeled necrosis-targeting probe for early Erasmus University Medical Creation of 11089 detection of anti-cancer therapy efficacy and anti-cancer Prof. Clemens Löwik Radiology / Nuclear Medicine Breast Cancer Imaging € 451.048,00 Center Rotterdam modality treatment: a new theranostic platform. Niche Inflammation and Clonal Evolution in Bone Marrow Failure Erasmus University Medical 11092 Dr. Marc Raaijmakers Hematology Credentialing Leukemia Basic research € 691.449,00 and Leukemia Center Rotterdam Bladder Cancer; Breast Cancer ; Boosting hyperthermia-based anticancer treatments by HSP90 Erasmus University Medical Head and Neck Cancer; 11143 Prof. Roland Kanaar Molecular Genetics Credentialing Agents € 591.391,00 inhibition Center Rotterdam Melanoma; Sarcoma (soft tissue); Urinary System Treating fear of cancer recurrence in primary care - effectiveness 10936 Dr. Marije van der Lee Helen Dowling Instituut Scientific Research Clinical Not Site-Specific Cancer Quality of life / care Alpe d'HuZes € 398.308,85 of a mental health worker led program Function and regulation of the fibrous corona of mitotic 11080 Prof. Geert Kops Hubrecht Institute Hubrecht Institute (department) Basic research Not Site-Specific Cancer Basic research € 636.620,50 kinetochores in the protection of genome stability Bacterial food poisoning and colon cancer; a cell biological and Leiden University Medical 11001 Prof. Jacques Neefjes Chemical Immunology Credentialing Colon and Rectal Cancer Basic research € 571.699,00 epidemiological study Center The Orthopedia Homeobox transcription factor (OTP) in lung Maastricht UMC+ (Maastricht GROW, School for Oncology and Creation of 10956 carcinoids: an indicator for metastatic progression or also a tumor Prof. Ernst Speel Lung Cancer Biomarkers € 498.431,66 University) Developmental Biology modality supressor? Energy balance, somatic mutations and metabolic subtypes in Maastricht UMC+ (Maastricht GROW, School for Oncology and 11044 colorectal cancer: studying etiology and prognosis using Prof. Piet van den Brandt Credentialing Colon and Rectal Cancer Lifestyle and exposure € 835.704,20 University) Developmental Biology molecular pathological epidemiology Achieving synergy between radiotherapy and immunotherapy to The Netherlands Cancer Immune response 10894 Dr. Inge Verbrugge Tumor biology & Immunology Basic research Breast Cancer; Lung Cancer Alpe d'HuZes € 679.585,00 increase control of metastatic cancer Institute modifiers New era of radiosensitization by modulating radiosensitizing The Netherlands Cancer Breast Cancer; Not Site-Specific 10902 Dr. Gerben Borst Radiotherapy Preclinical Interventive devices € 675.831,00 agents during RT Institute Cancer A risk prediction tool for cardiovascular disease in breast cancer The Netherlands Cancer Psychosocial Research and 10933 Prof. Flora E. van Leeuwen Credentialing Breast Cancer Quality of life / care Pink Ribbon € 437.130,00 patients Institute Epidemiology Mechanisms of DNA repair pathway control at DNA double-strand The Netherlands Cancer 10999 Dr. Jacqueline Jacobs Oncogenomics Basic research Not Site-Specific Cancer Basic research € 596.318,00 breaks and telomeres Institute The Netherlands Cancer 11037 Exploiting proline vulnerability for cancer therapy Prof. Reuven Agami Oncogenomics Basic research Not Site-Specific Cancer Basic research € 807.549,00 Institute The Netherlands Cancer 11074 Targeting replication rescue pathways Prof. Hein te Riele Tumor biology & Immunology Basic research Head and Neck Cancer Basic research € 755.344,00 Institute The Netherlands Cancer Immune response 11079 Cytotoxic T cell programming at the dendritic cell interface Prof. Jannie Borst Tumor biology & Immunology Basic research Not Site-Specific Cancer € 618.318,00 Institute modifiers Postpartum breast cancer diagnosed during involution: a distinct The Netherlands Cancer 11132 entity with unique clinicopathological, molecular and Prof. Frédéric Amant Medical Oncology Basic research Breast Cancer Basic research € 639.210,27 Institute immunological features? Radiosensitization of glioma through induction of mitotic The Netherlands Cancer 11165 Dr. Olaf van Tellingen Diagnostic Oncology Preclinical Brain Tumor Agents € 394.321,50 enrichment Institute The clonal relationship and mutational landscape of B-cell Radboud University Medical Hodgkin's Disease; Non- 11137 Prof. Han van Krieken Pathology Credentialing Biomarkers € 597.116,00 lymphoma recurrences: a key to tailored treatment Center Hodgkin's Lymphoma MRI-guided focal salvage high dose rate brachytherapy for Dr. Jochem van der Voort van 10932 UMC Utrecht Imaging Clinical Prostate Cancer Interventive devices € 323.925,60 radiorecurrent prostate cancer Zyp Improved prediction and early detection of recurrent laryngeal 10978 Dr. Stefan Willems UMC Utrecht Laboratories & Pharmacy Credentialing Head and Neck Cancer Biomarkers € 497.402,00 carcinoma Personalized strategy to avert drug resistance in hematologic Creation of 11108 Dr. Victor Peperzak UMC Utrecht Laboratories & Pharmacy Blood Cancer; Leukemia Agents Alpe d'HuZes € 516.464,00 cancers modality
11110 Cognitive Functioning After Brain Irradiation Informed by MRI Dr. ir. Marielle Philippens UMC Utrecht UMC Utrecht Cancer Center Credentialing Not Site-Specific Cancer Imaging € 635.728,50
EORTC-1308: Radiation versus Observation following surgical 11111 resection of Atypical Meningioma: a randomised controlled trial Dr. Joost Verhoeff UMC Utrecht UMC Utrecht Cancer Center Clinical Nervous System Interventive devices € 56.476,00 (The ROAM trial) Accelerated ageing in cancer survivors: Senescence EArly after University Medical Center 10861 Chemotherapy for testicular cAncer treatment: Time to act (SEA- Prof. Jourik Gietema Medical Oncology Clinical Testicular Cancer Quality of life / care € 746.132,00 Groningen CAT) Characterization of UV-induced senescent cells during melanoma University Medical Center 10989 Dr. Marco Demaria Ageing Biology Basic research Melanoma Basic research € 615.475,00 progression Groningen Modulation of the TSC-mTORC1-mitochondrial pathway for University Medical Center Blood Cancer; Leukemia; Lung 11010 Prof. Cor Calkhoven Ageing Biology Basic research Basic research € 647.459,00 suppression of MYC-driven tumourigenesis Groningen Cancer Using the plasma membrane proteome to dissect clonal University Medical Center 11013 Prof. Jan Jacob Schuringa Hematology Basic research Leukemia Basic research € 579.402,00 heterogeneity and track disease progression in AML Groningen Towards evidence-based and broadly supported protocols for University Medical Center Creation of Breast Cancer; Colon and Rectal 11062 Dr. Annette Berendsen General Practice Quality of life / care € 276.605,57 cancer follow-up in primary care Groningen modality Cancer EORTC-1301-LG: 10-day decitabine versus conventional University Medical Center 11072 chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 Prof. Gerwin Huls Hematology Clinical Leukemia Agents € 139.150,00 Groningen years (extension approved KWF grant) Swammerdam Institute for Life 11082 Dissecting the role of aberrant Wnt signaling in breast cancer Dr. Renee van Amerongen University of Amsterdam Basic research Breast Cancer Basic research € 517.035,00 Sciences
Unraveling the role of signaling networks controlled by Leiden Academic Centre for Drug 10967 Dr. Erik Danen University of Leiden Basic research Breast Cancer Basic research € 495.692,80 Grainyhead like transcription factor in breast cancer subtypes Research (LACDR)
Drug-atlas based prediction of multi-drug combinations against 11038 Dr. Bart Westerman VU University Medical Centre Neurosurgery (VUmc CCA) Basic research Nervous System Agents € 444.503,90 glioblastoma Exosomes-driven alterations of mesenchymal stem cell Immune response 11065 immunomodulatory properties as novel therapeutic targets for Dr. Serena Rubina Baglio VU University Medical Centre Pathology (VUmc CCA) Credentialing Bone Cancer € 523.532,95 modifiers osteosarcoma Total funding Research Projects (43 projects): € 22.674.717,97
YOUNG INVESTIGATOR GRANTS
Project Project Title Project Leader Institute Department Research Phase Tumor type Mission Goal(s) Assigned Funder Approved budget Number
Tytgat Institute for Liver and 11053 ER-stress and Grp78 during intestinal carcinogenesis Dr. Jarom Heijmans Academic Medical Center Basic research Colon and Rectal Cancer Basic research Alpe d'HuZes € 613.505,75 Intestinal Research Dissecting the mechanisms of malignant transformation in Dr. Rebekka Schneider- Erasmus University Medical 11031 del(5q) myelodysplastic syndrome to selectively target the disease- Hematology Basic research Blood Cancer Basic research Alpe d'HuZes € 506.273,00 Kramann Center Rotterdam initiating hematopoietic stem cells
The causes and effect of variation in the curative treatment of 10895 Dr. Rob Verhoeven IKNL Research Credentialing Oesophageal; Stomach Cancer Quality of life / care Alpe d'HuZes € 551.465,90 esophageal and gastric cancer: A mixed methods approach Head and Neck Cancer; Oncolytic viruses, a generic approach to sensitize tumours for Dr. Nadine Pronk - van Leiden University Medical Melanoma; Ovarian Cancer; Immune response 11056 Clinical Oncology Credentialing Alpe d'HuZes € 518.687,72 cancer immunotherapy Montfoort Center Pancreatic Cancer; Vaginal modifiers Cancer; Vulva Cancer ROGUE: Radiosensitization Of high-grade Glioma and diffuse Princess Maxima Center for Creation of 10911 intrinsic pontine glioma by focused Ultrasound-mediated drug Dr. Dannis Van Vuurden Research Operations Nervous System Agents Alpe d'HuZes € 499.965,00 Pediatric Oncology modality Engagement
10957 The RSPO-LGR signaling pathway as a driver of breast cancer Dr. Elvira Bakker UMC Utrecht Laboratories & Pharmacy Basic research Breast Cancer Basic research Alpe d'HuZes € 665.465,55
Precision Thyroid cAncer surgery with intraoperative molecular University Medical Center 10851 fluoRescent Guided imaging to rEduce overtreatmenT and Dr. Schelto Kruijff Surgery Clinical Thyroid Cancer Interventive devices Alpe d'HuZes € 611.684,00 Groningen postoperative morbidity (TARGET)
TArgeting Metabolism to Improve response to immune- University Medical Center 10913 Dr. Mathilde Jalving Medical Oncology Clinical Melanoma Agents Alpe d'HuZes € 477.492,40 Checkpoint inhibition in melanoma (TAMIC) Groningen
Preventing radiation-induced neurocognitive dysfunction in University Medical Center Creation of 11148 patients with paediatric brain tumours: biological mechanisms Dr. Lara Barazzuol Radiotherapy Brain Tumor Quality of life / care Alpe d'HuZes € 495.958,50 Groningen modality and potential role of proton therapy
Towards OPtimal TIming and Method for promoting sUstained 10960 adherence to lifestyle and body weight recommendations in Dr. Meeke Hoedjes VU University Amsterdam Health Sciences (FALW) Basic research Breast Cancer Lifestyle and exposure Alpe d'HuZes € 505.432,80 postMenopausal breast cancer survivors.
Total funding Young Investigator Grants (10 projects): € 5.445.930,62 CONSORTIA
Project Project Title Project Leader Institute Department Research Phase Tumor type Mission Goal(s) Assigned Funder Approved budget Number
NeoVAC: a novel nanotechnology platform using neoantigen- Leiden University Medical Immunohematology and Blood Creation of Colon and Rectal Cancer; Immune response 11157 Prof. Ferry Ossendorp € 705.363,00 encoding DNA for personalised specific immunotherapy Center Transfusion modality Melanoma modifiers
Improving breast cancer screening among young high risk women The Netherlands Cancer 11105 Dr. Esther Lips Molecular Pathology Credentialing Breast Cancer Biomarkers Pink Ribbon € 605.849,50 by blood-based methods Institute Glioma Longitudinal AnalySiS in the Netherlands (GLASS-NL): 11026 Molecular and imaging markers for malignant evolution of IDH- Prof. Pieter Wesseling VU University Medical Centre Pathology (VUmc CCA) Credentialing Brain Tumor Biomarkers € 1.218.641,20 mutant astrocytomas. Total funding Consortia (3 projects): € 2.529.853,70 UNIQUE HIGH RISK PROJECTS
Project Project Title Project Leader Institute Department Research Phase Tumor type Mission Goal(s) Assigned Funder Approved budget Number
TRACE and RECALL clonal population dynamics to model Center of Experimental and 10906 Dr. Nicolas Leveille Academic Medical Center Basic research Colon and Rectal Cancer Basic research Alpe d'HuZes € 149.695,00 colorectal cancer tumor growth Molecular Medicine Developing a validated Cancer-on-Chip prototype for personalized Erasmus University Medical 11011 Dr. Dik van Gent Molecular Genetics Credentialing Breast Cancer Biomarkers Alpe d'HuZes € 170.420,00 medicine Center Rotterdam Erasmus University Medical 11125 Nuclear EGFR in Glioblastomas as a target for therapy Dr. Pim French Neurology Basic research Brain Tumor Basic research Alpe d'HuZes € 165.042,00 Center Rotterdam
Trojan horses against cancer: the use of harmless clostridia Maastricht UMC+ (Academic Academic Hospital Maastricht Creation of Immune response 11163 bacteria to continuously produce immunomodulatory anti-cancer Prof. Philippe Lambin Not Site-Specific Cancer Alpe d'HuZes € 152.042,00 Hospital Maastricht) (azM) modality modifiers agents specifically within the tumor
Challenging the dogmatic use of ABL1-directed tyrosine kinase Princess Maxima Center for 11117 Prof. Monique den Boer Research Operations Credentialing Leukemia Biomarkers Alpe d'HuZes € 149.028,00 inhibitors in BCR-ABL1-positive acute lymphoblastic leukemia Pediatric Oncology
Tailored lymphadenectomy using Sentinel node Navigation Internal Medicine & 10944 surgery in submucosal esophageal Adenocarcinoma Patients: Prof. Bas Weusten UMC Utrecht Clinical Oesophageal Interventive devices Alpe d'HuZes € 201.484,50 Dermatology SNAP-II study Towards understanding molecular and pre-clinical aspects of loss Colon and Rectal Cancer; Not 11077 Dr. Tobias Dansen UMC Utrecht Biomedical Genetics Basic research Basic research Alpe d'HuZes € 267.388,50 of protein homeostasis in cancer. Site-Specific Cancer Exploring the immunomodulatory activity of galectin-cytokine 11040 Dr. Victor Thijssen VU University Medical Centre Radiation Oncology (VUmc CCA) Basic research Not Site-Specific Cancer Basic research Alpe d'HuZes € 173.819,50 interactions Total funding Unique High Risk Projects (8 projects): € 1.428.919,50 INFRASTRUCTURAL INITIATIVES
Project Project Title Project Leader Institute Approved budget Number
Facilitating power: collecting and managing international data on Leiden University Medical 8223 Dr. M. Nielsen € 45.560,48 (rare) colorectal cancer predisposition syndromes. Center Dutch Hepatocellular Carcinoma Group biobank and prospective Leiden University Medical 8242 Dr. M.J. Coenraad € 440.251,00 database Center CustoMICE: a facility for production and distribution of The Netherlands Cancer 8231 Prof. ir. J. Jonkers € 866.548,00 engineered mouse models for cancer research Institute Biobank of 5-year lymphoma survivors as a resource to examine The Netherlands Cancer 8237 susceptibility genes and biomarkers for late effects of cancer Prof. ir. F.E. van Leeuwen € 938.388,60 Institute treatment. The Netherlands Cancer 8244 Netherlands facility for Cancer-Immune Analysis (N-CIA) Prof. T.N.M. Schumacher € 3.648.008,40 Institute University Medical Center 8254 Proton therapy research infrastructure - ProTRAIT Prof. J.A. Langendijk € 1.545.098,60 Groningen GENomics portal for precision medicine research in ONCOlogy: 8225 Prof. ir. E. Cuppen UMC Utrecht € 1.600.778,00 GENONCO Total funding Infrastructural initiatives (7 projects): € 9.084.633,08 IMPLEMENTATION PROJECTS
Project Project Title Project Leader Institute Approved budget Number
Nationwide implementation of standardized structured reporting Radboud University Medical 8281 Dr. R.P.M.G. Hermens € 264.352,43 to support optimal treatment decisions Center
Postoperative Standardization of Care; the implementation of 8272 Dr. H.C. van Santvoort UMC Utrecht € 555.422,00 best practice after pancreatic resection (PORSCH trial)
Total Funding Implementation projects (2 projects): € 819.774,43
Total funding CALL 2017-I: € 41.983.829,30 OVERVIEW
Research tracks & research phases Number of projects Funding Funding types & research phases Number of projects Funding Exploration track 38 € 20.970.175,54 Consortia 3€ 2.529.853,70 Basic research 23 € 12.374.930,57 Creation of modality 1€ 705.363,00 Credentialing 15 € 8.595.244,97 Credentialing 2€ 1.824.490,70 Development track 26 € 11.109.246,25 Research Project 43€ 22.674.717,97 Creation of modality 9 € 4.179.767,99 Basic research 15€ 9.328.308,47 Preclinical 2 € 1.070.152,50 Credentialing 9€ 5.381.152,65 Clinical 15 € 5.859.325,76 Creation of modality 5€ 2.326.439,49 Infrastrucural initiatives 7 € 9.084.633,08 Preclinical 2€ 1.070.152,50 Implementation projects 2 € 819.774,43 Clinical 12€ 4.568.664,86 Total 73€ 41.983.829,30 Unique High Risk Project 8€ 1.428.919,50 Basic research 4€ 755.945,00 Credentialing 2€ 319.448,00 Creation of modality 1€ 152.042,00 Clinical 1€ 201.484,50 Young Investigator Grant 10€ 5.445.930,62 Basic research 4€ 2.290.677,10 Creation of modality 2€ 995.923,50 Clinical 2€ 1.089.176,40 Credentialing 2€ 1.070.153,62 Infrastructure 7€ 9.084.633,08 Implementation 2€ 819.774,43 Total funding CALL 2017-1 73€ 41.983.829,30